IN2012DN01292A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01292A
IN2012DN01292A IN1292DEN2012A IN2012DN01292A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A IN 1292DEN2012 A IN1292DEN2012 A IN 1292DEN2012A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A
Authority
IN
India
Prior art keywords
therapy
preparing
processes
compound
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Simon Craig Andrew
Zarah Ismail Salima
Maxwell Lawrence Ronnie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2012DN01292A publication Critical patent/IN2012DN01292A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1292DEN2012 2009-08-27 2010-08-25 IN2012DN01292A (th)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
IN2012DN01292A true IN2012DN01292A (th) 2015-06-05

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1292DEN2012 IN2012DN01292A (th) 2009-08-27 2010-08-25

Country Status (18)

Country Link
US (1) US8796269B2 (th)
EP (1) EP2470545B1 (th)
JP (3) JP2013503134A (th)
KR (1) KR20120056258A (th)
CN (1) CN102639536B (th)
AU (1) AU2010288502B2 (th)
BR (1) BR112012003435A2 (th)
CA (1) CA2772168C (th)
DK (1) DK2470545T3 (th)
EA (1) EA021411B1 (th)
ES (1) ES2440938T3 (th)
IL (1) IL217922A (th)
IN (1) IN2012DN01292A (th)
MX (1) MX2012002369A (th)
PL (1) PL2470545T3 (th)
SG (1) SG178231A1 (th)
WO (1) WO2011023733A1 (th)
ZA (1) ZA201200812B (th)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
EP3160469B1 (en) * 2014-06-25 2021-04-28 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
HUE047732T2 (hu) * 2015-05-18 2020-05-28 Nerre Therapeutics Ltd NK-1/NK-3 receptor antagonista vértolulások kezeléséhez
BR112019012300A2 (pt) * 2016-12-15 2019-11-12 Glaxosmithkline Ip Dev Ltd ativadores nrf2
UA128159C2 (uk) * 2018-03-14 2024-04-24 Канді Терап'Ютікс Лімітед Фармацевтичний препарат для капсули з м'якого желатину, який містить подвійний антагоніст рецептора nk-1/nk-3
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
CA3161336A1 (en) 2019-11-15 2021-05-20 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496032T1 (de) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
JP5121716B2 (ja) * 2005-09-09 2013-01-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ピリジン誘導体および精神異常の処置におけるそれらの使用
US20100190797A1 (en) * 2007-12-11 2010-07-29 Cipla Ltd. Crystalline polymophic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
JP2013503134A (ja) 2013-01-31
JP2017193564A (ja) 2017-10-26
IL217922A0 (en) 2012-03-29
IL217922A (en) 2016-06-30
US8796269B2 (en) 2014-08-05
EP2470545A1 (en) 2012-07-04
ZA201200812B (en) 2013-03-27
EP2470545B1 (en) 2013-10-09
CN102639536B (zh) 2015-03-18
CA2772168C (en) 2019-01-08
US20120157450A1 (en) 2012-06-21
AU2010288502A1 (en) 2012-02-23
EA201270302A1 (ru) 2012-07-30
JP2016000739A (ja) 2016-01-07
WO2011023733A1 (en) 2011-03-03
BR112012003435A2 (pt) 2016-02-23
DK2470545T3 (da) 2014-01-13
MX2012002369A (es) 2012-03-29
SG178231A1 (en) 2012-03-29
CA2772168A1 (en) 2011-03-03
KR20120056258A (ko) 2012-06-01
JP6404186B2 (ja) 2018-10-10
PL2470545T3 (pl) 2014-03-31
CN102639536A (zh) 2012-08-15
EA021411B1 (ru) 2015-06-30
AU2010288502B2 (en) 2013-12-12
ES2440938T3 (es) 2014-01-31

Similar Documents

Publication Publication Date Title
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY149731A (en) Compounds
NZ608116A (en) Triazine-oxadiazoles
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
IN2012DN01292A (th)
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
IN2014CN04530A (th)
IN2012DN03182A (th)
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MY187718A (en) Pharmaceutical formulations
IN2012DN02139A (th)
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
IN2015DN01119A (th)
MX2011011776A (es) Nuevos profarmacos de triptolite.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
IN2012DN02698A (th)
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.